Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
about
Store-operated Ca2+ entry (SOCE) regulates melanoma proliferation and cell migrationIntegrative modelling of the influence of MAPK network on cancer cell fate decisionExtranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models.Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer.
P2860
Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular targeted therapy for ...... pathway inhibition and beyond.
@en
Molecular targeted therapy for ...... pathway inhibition and beyond.
@nl
type
label
Molecular targeted therapy for ...... pathway inhibition and beyond.
@en
Molecular targeted therapy for ...... pathway inhibition and beyond.
@nl
prefLabel
Molecular targeted therapy for ...... pathway inhibition and beyond.
@en
Molecular targeted therapy for ...... pathway inhibition and beyond.
@nl
P2860
P1476
Molecular targeted therapy for ...... pathway inhibition and beyond.
@en
P2093
Michael B Atkins
Ryan J Sullivan
P2860
P304
P356
10.1517/13543784.2010.504709
P407
P577
2010-10-01T00:00:00Z